ArticleProceedings of the National Academy of Sciences of the United States of America2013
Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 155 citations in OpenAlex.
- Evidence of cefiderocol-persistence inBiofilm · 2026Article
- Trojan Horses: Conjugating Siderophores and Antibiotics-A New Approach to TreatingMicroorganisms · 2026Review
- Special Issue "Novel Mechanisms of Bacterial Antibiotic Resistance and Strategies to Fight Them".International journal of molecular sciences · 2026Article
- Repurposing Tirazone as an effective quorum-sensing inhibitor against Pseudomonas aeruginosa virulence and biofilm formation.The Journal of antibiotics · 2026Article
- 5-Fluorouracil modulates motility and biofilm-associated gene expression in Pseudomonas aeruginosa.PloS one · 2026Article
- Comprehensive Theoretical, Spectroscopic, Solvent, Topological and Antimicrobial investigation of 5-Chloro-6-fluoro-2-(2-pyrazinyl)-1H-benzimidazole.Scientific reports · 2025Article
- Functional interplay between RND efflux pumps and GacS inApplied and environmental microbiology · 2025Article
- New Frontiers for Old Medications: Repurposing Approved Drugs Against Gram-Negative Bacterial Infections.Microorganisms · 2025Review
- Dual-species proteomics and targeted intervention of animal-pathogen interactions.Journal of advanced research · 2025Article
- Antibacterial Siderophores of Pandoraea Pathogens and Their Impact on the Diseased Lung Microbiota.Angewandte Chemie (International ed. in English) · 2025Article
- Cleavage cascade of the sigma regulator FecR orchestrates TonB-dependent signal transduction.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The antimycotic 5-fluorocytosine is a virulence inhibitor of uropathogenicAntimicrobial agents and chemotherapy · 2025Article
- Reprofiling lamivudine as an antibiofilm and anti-pathogenic agent against Pseudomonas aeruginosa.AMB Express · 2025Article
- Article
- Host-mimicking conditions promoteFrontiers in microbiology · 2025Article
- Exploiting haem-iron dependence of nontypeableFrontiers in cellular and infection microbiology · 2025Review
- EF-hand calcium sensor, EfhP, controls transcriptional regulation of iron uptake by calcium inmBio · 2024Article
- 5-Fluorouracil Inhibits Bacterial Growth and Reduces Biofilm in Addition to Having Synergetic Effects with Gentamicin AgainstMicroorganisms · 2024Article
- New 24-Membered Macrolactines from an Arctic BacteriumMarine drugs · 2024Article
- Deciphering the Antibacterial Mechanisms of 5-Fluorouracil inAntibiotics (Basel, Switzerland) · 2024Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although antibiotic resistance represents a public health emergency, the pipeline of new antibiotics is running dry. Repurposing of old drugs for new clinical applications is an attractive strategy for drug development. We used the bacterial pathogen Pseudomonas aeruginosa as a target for the screening of antivirulence activity among marketed drugs. We found that the antimycotic agent flucytosine inhibits the expression of the iron-starvation σ-factor PvdS, thereby repressing the production of major P. aeruginosa virulence factors, namely pyoverdine, PrpL protease, and exotoxin A. Flucytosine administration at clinically meaningful dosing regimens suppressed P. aeruginosa pathogenicity in a mouse model of lung infection. The in vitro and in vivo activity of flucytosine against P. aeruginosa, combined with its desirable pharmacological properties, paves the way for clinical trials on the anti-P. aeruginosa efficacy of flucytosine in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.